Get the Stockscreener App
5.56
3.30%
-0.19
After Hours:
5.47
-0.09
-1.62%
Solid Biosciences Inc stock is traded at $5.56, with a volume of 659.57K.
It is down -3.30% in the last 24 hours and down -18.48% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$5.75
Open:
$5.76
24h Volume:
659.57K
Relative Volume:
0.47
Market Cap:
$432.95M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.8289
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
-1.07%
1M Performance:
-18.48%
6M Performance:
+4.71%
1Y Performance:
-34.59%
1-Day Range:
$5.41
$5.76
1-Week Range:
$5.34
$5.77
52-Week Range:
$2.41
$8.745
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.56 | 422.83M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
What’s Solid Biosciences Inc.’s historical returnQuarterly Trade Review & Risk Managed Investment Strategies - khodrobank.com
Technical analysis overview for Solid Biosciences Inc. stockGold Moves & Risk Controlled Stock Alerts - Newser
Is Solid Biosciences Inc. meeting your algorithmic filter criteriaWatch List & Momentum Based Trading Ideas - Newser
Is Solid Biosciences Inc. stock a value trap2025 Macro Impact & AI Powered Market Entry Strategies - khodrobank.com
What the charts say about Solid Biosciences Inc. todayMarket Sentiment Review & Weekly High Return Stock Forecasts - Newser
How sentiment analysis helps forecast Solid Biosciences Inc.Profit Target & Risk Controlled Swing Alerts - Newser
Risk On: What’s the MACD signal for Solid Biosciences Inc.Trade Exit Summary & Community Consensus Stock Picks - khodrobank.com
Will Solid Biosciences Inc. bounce back from current supportTrend Reversal & Capital Protection Trade Alerts - Newser
Using economic indicators to assess Solid Biosciences Inc. potentialEarnings Risk Report & Community Driven Trade Alerts - Newser
News impact scoring models applied to Solid Biosciences Inc.July 2025 Decliners & Verified Momentum Stock Ideas - Newser
Real time breakdown of Solid Biosciences Inc. stock performanceMarket Performance Report & Free Long-Term Investment Growth Plans - Newser
Applying Wyckoff theory to Solid Biosciences Inc. stockStop Loss & Free Weekly Watchlist of Top Performers - Newser
What moving averages say about Solid Biosciences Inc.New Guidance & Daily Price Action Insights - Newser
Solid Biosciences Inc. stock retracement – recovery analysisEarnings Growth Report & Stepwise Swing Trade Plans - Newser
Is Solid Biosciences Inc. stock entering bullish territory2025 Macro Impact & Free Accurate Trade Setup Notifications - Newser
How moving averages guide Solid Biosciences Inc. tradingJuly 2025 Recap & Daily Price Action Insights - Newser
Analyzing Solid Biosciences Inc. with multi timeframe chartsAnalyst Downgrade & Fast Entry High Yield Stock Tips - Newser
Custom watchlist performance reports with Solid Biosciences Inc.Market Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - Newser
How is Solid Biosciences Inc. managing supply chain issuesWeekly Earnings Recap & Growth Oriented Trading Recommendations - khodrobank.com
Trend Report: What is Solid Biosciences Inc.’s TAM (Total Addressable Market)July 2025 Highlights & High Accuracy Investment Signals - khodrobank.com
Will Solid Biosciences Inc. benefit from government policyJuly 2025 Recap & Fast Moving Stock Trade Plans - خودرو بانک
How to use Fibonacci retracement on Solid Biosciences Inc.Market Weekly Review & Fast Exit/Entry Strategy Plans - Newser
Can Solid Biosciences Inc. stock outperform in a bear marketJuly 2025 Highlights & Daily Risk Controlled Trade Plans - khodrobank.com
Solid Biosciences Inc. stock prediction for this weekBuy Signal & Safe Capital Preservation Plans - Newser
What is Solid Biosciences Inc.’s valuation compared to sectorMarket Sentiment Report & Real-Time Buy Zone Alerts - khodrobank.com
Using R and stats models for Solid Biosciences Inc. forecastingPortfolio Update Report & AI Enhanced Execution Alerts - Newser
Is Solid Biosciences Inc. stock poised for growthPortfolio Risk Summary & Technical Pattern Alert System - Newser
Will Solid Biosciences Inc. stock benefit from interest rate changesRecession Risk & Real-Time Market Trend Scan - Newser
Will a bounce in Solid Biosciences Inc. offer an exit2025 Dividend Review & Risk Managed Investment Strategies - Newser
What candlestick patterns are forming on Solid Biosciences Inc.July 2025 Reactions & High Yield Stock Recommendations - Newser
Is this a good reentry point in Solid Biosciences Inc.July 2025 Fed Impact & Scalable Portfolio Growth Methods - Newser
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Solid Biosciences Inc Stock (SLDB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
| Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):